Monday, November 9, 2026

BGC Partners, Inc. And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

BGC Partners, Inc. And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Quidel Corporation

197.5% sales growth and 85.63% return on equity

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide.

Quidel Corporation's sales growth this year is anticipated to be 38.8% and a negative 37.9% for next year.

Year-on-year quarterly revenue growth grew by 431.7%, now sitting on 1.66B for the twelve trailing months.

Quidel Corporation's sales growth for the next quarter is 197.5%. The company's growth estimates for the ongoing quarter and the next is 318.9% and 238.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 85.63%.

Volatility

Quidel Corporation's last day, last week, and last month's current volatility was 4.16%, 1.73%, and 2.39%, respectively.

Quidel Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.77% (day), 4.13% (last week), and 4.95% (last month), respectively.

Quidel Corporation's Stock Yearly Top and Bottom Value

Quidel Corporation's stock is valued at $127.30 at 05:22 EST, way below its 52-week high of $306.72 and way higher than its 52-week low of $86.30.

Quidel Corporation's Moving Average

Quidel Corporation's worth is way under its 50-day moving average of $151.95 and way below its 200-day moving average of $203.14.

3. Quaker Chemical Corporation

34.2% sales growth and 3.1% return on equity

Quaker Chemical Corporation develops, produces, and markets various formulated chemical specialty products for a range of heavy industrial and manufacturing applications.

Quaker Chemical Corporation's sales growth this year is expected to be 11.4% and 4.3% for next year.

Year-on-year quarterly revenue growth declined by 1.4%, now sitting on 1.42B for the twelve trailing months.

Quaker Chemical Corporation's sales growth for the next quarter is 34.2%. The company's growth estimates for the current quarter and the next is 5.8% and 661.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.1%.

Volatility

Quaker Chemical Corporation's last day, last week, and last month's current volatility was 0.29%, 1.41%, and 1.33%, respectively.

Quaker Chemical Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.49% (day), 2.53% (last week), and 3.17% (last month), respectively.

Quaker Chemical Corporation's Stock Yearly Top and Bottom Value

Quaker Chemical Corporation's stock is valued at $245.18 at 05:22 EST, way under its 52-week high of $301.99 and way higher than its 52-week low of $119.18.

Quaker Chemical Corporation's Moving Average

Quaker Chemical Corporation's worth is under its 50-day moving average of $254.47 and higher than its 200-day moving average of $243.74.

4. Lam Research Corporation

32% sales growth and 59.99% return on equity

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits in the United States, China, Europe, Japan, Korea, Taiwan, and the southeast Asia.

Lam Research Corporation's sales growth this year is expected to be 40% and 5% for next year.

Year-on-year quarterly revenue growth grew by 33.8%, now sitting on 11.93B for the twelve trailing months.

Lam Research Corporation's sales growth for the next quarter is 32%. The company's growth estimates for the current quarter and the next is 65.8% and 40.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 59.99%.

Volatility

Lam Research Corporation's last day, last week, and last month's current volatility was 0.91%, 1.58%, and 2.42%, respectively.

Lam Research Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.85% (day), 2.88% (last week), and 3.68% (last month), respectively.

Lam Research Corporation's Stock Yearly Top and Bottom Value

Lam Research Corporation's stock is valued at $650.27 at 05:22 EST, below its 52-week high of $659.60 and way above its 52-week low of $229.69.

Lam Research Corporation's Moving Average

Lam Research Corporation's worth is way higher than its 50-day moving average of $560.79 and way above its 200-day moving average of $472.03.

5. BGC Partners, Inc.

6.8% sales growth and 7.18% return on equity

BGC Partners, Inc. operates as a brokerage and financial technology company in the United States, the United Kingdom, rest of Asia, France, the Middle East, Africa, rest of Europe, and internationally.

BGC Partners, Inc.'s sales growth this year is expected to be 7.5% and 5.9% for next year.

Year-on-year quarterly revenue growth declined by 2.8%, now sitting on 1.98B for the twelve trailing months.

BGC Partners, Inc.'s sales growth for the next quarter is 6.8%. The company's growth estimates for the present quarter and the next is a negative 5.3% and 6.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.18%.

Volatility

BGC Partners, Inc.'s last day, last week, and last month's current volatility was 1.13%, 3.56%, and 2.60%, respectively.

BGC Partners, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.23% (day), 6.78% (last week), and 5.31% (last month), respectively.

BGC Partners, Inc.'s Stock Yearly Top and Bottom Value

BGC Partners, Inc.'s stock is valued at $5.38 at 05:22 EST, below its 52-week high of $5.67 and way above its 52-week low of $2.22.

BGC Partners, Inc.'s Moving Average

BGC Partners, Inc.'s value is way above its 50-day moving average of $4.61 and way higher than its 200-day moving average of $3.82.

6. Stepan Company

16.5% sales growth and 13.57% return on equity

Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in North America, Europe, Latin America, and Asia.

Stepan Company's sales growth this year is expected to be 12.2% and 4.7% for next year.

Year-on-year quarterly revenue growth grew by 11.2%, now sitting on 1.87B for the twelve trailing months.

Stepan Company's sales growth for the next quarter is 16.5%. The company's growth estimates for the present quarter and the next is 31.7% and 12.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.57%.

Volatility

Stepan Company's last day, last week, and last month's current volatility was 2.50%, 1.15%, and 1.17%, respectively.

Stepan Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.36% (day), 2.06% (last week), and 2.16% (last month), respectively.

Stepan Company's Stock Yearly Top and Bottom Value

Stepan Company's stock is valued at $126.49 at 05:22 EST, under its 52-week high of $131.72 and way higher than its 52-week low of $83.66.

Stepan Company's Moving Average

Stepan Company's worth is higher than its 50-day moving average of $125.77 and higher than its 200-day moving average of $120.21.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com